Evolution in Immune Gene Therapy of Glioblastoma; Interleukin-37 as a Novel Candidate

Elnaz Khosh, Nazila Bahmaie and Abdolreza Esmaeilzadeh

Zanjan University of Medical Sciences, Iran
Department of Immunology and Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Iran

^*Correspondance to: Abdolreza Esmaeilzadeh 

 PDF  Full Text Research Article | Open Access

Abstract:

Glioblastoma (GBM), as grade IV of glioma in nervous system, is one of the most invasive cancers which its survival rate is about 12 to 15 months. In spite of main therapeutics or preventive procedures such as surgery, radiotherapy and chemotherapy for this aggressive tumor, there is no confirmed explicit advancement. Thus, nowadays more investigations on appropriation of efficient strategies for those kinds of tumors, is of particular importance. Fortunately, exponential growth of target therapies especially with immunological perspectives has opened glittering windows to our significant challenges. One of these lately a novel method is immune gene therapy in which, cytokine genes majorly is being administrated in order to immune regulation. Interleukin-37 (IL-37) is one of those cytokines which displays anti-tumor function and has been focused in attraction of basic scientist`s attention. Here, we propose that it could berationalto investigate anti-tumoral role of IL- 37 by utilizing CNS-1 cell line in GBM-induced microenvironment of a syngeneic Lewis rat in order to diminish patients’ sufferings, oncologist’s considerations and exorbitant social expenditures.

Keywords:

Glioblastoma; Interleukin-37; Immune gene therapy; Anti-angiogenesis; Immuneregulation; Immunotherapy

Cite the Article:

Khosh E, Bahmaie N, Esmaeilzadeh A. Evolution in Immune Gene Therapy of Glioblastoma; Interleukin-37 as a Novel Candidate. Clin Oncol. 2019; 4: 1618.